+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Velcade

  • ID: 4775164
  • Report
  • 31 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Velcade (bortezomib; Takeda/Johnson & Johnson) is an intravenously or subcutaneously administered 26S proteasome inhibitor that affects multiple signaling cascades and induces cell death.

In preclinical studies, Velcade has been shown to induce apoptosis and sensitize tumor cells to chemotherapy or radiation.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Velcade : Multiple myeloma
Velcade : NHL: Mantle cell lymphoma (MCL)

LIST OF FIGURES
Figure 1: Velcade for multiple myeloma – SWOT analysis
Figure 2: The authors drug assessment summary of Velcade for multiple myeloma
Figure 3: The authors drug assessment summary of Velcade for multiple myeloma
Figure 4: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Velcade for mantle cell lymphoma – SWOT analysis
Figure 6: The authors drug assessment summary of Velcade in mantle cell lymphoma
Figure 7: The authors drug assessment summary of Velcade in mantle cell lymphoma

LIST OF TABLES
Table 1: Velcade drug profile
Table 2: Velcade pivotal trial data in multiple myeloma
Table 3: Velcade late-phase trial data in multiple myeloma
Table 4: Velcade sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Patients treated with Velcade in the US, Japan, and five major EU markets, by country, 2017–26
Table 6: Velcade drug profile
Table 7: Velcade pivotal trial data in mantle cell lymphoma
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll